Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Comprehensive Overview
This study, published in the New England Journal of Medicine (2019), tested whether a new three-drug combination could help people with cystic fibrosis, an inherited disease caused by mutations in a gene that controls salt and fluid movement across cell surfaces, leading to thick, sticky mucus that damages the lungs and digestive system. Nearly 90 percent of people with cystic fibrosis carry at least one copy of the most common disease-causing mutation, called Phe508del, but earlier drug combinations had not been effective for patients who carry this mutation alongside a second, more severe mutation that produces little or no working protein at all. Researchers conducted a randomized, double-blind, placebo-controlled trial in 403 patients age 12 and older with this specific mutation combination, assigning them to receive either the triple-drug regimen, elexacaftor-tezacaftor-ivacaftor, or a placebo for 24 weeks. They then measured changes in lung function, flare-ups of respiratory symptoms, and other markers of disease severity. Patients receiving the triple combination showed substantial improvement in lung function within just four weeks, a benefit that was sustained through the full 24-week study period, along with meaningful improvements across multiple other measures of disease severity.
Outcomes and Implications
The most notable finding was that patients taking the triple-drug combination saw their lung function, measured as forced expiratory volume, improve by nearly 14 percentage points more than patients taking placebo, a large and clinically meaningful gain that appeared quickly and held steady throughout the six-month study. Patients on active treatment also had roughly 63 percent fewer flare-ups of respiratory symptoms, known as pulmonary exacerbations, episodes that often require hospitalization or antibiotics and drive much of the long-term lung damage in cystic fibrosis. Patient-reported quality of life related to breathing improved substantially as well, by about five times more than the threshold researchers consider clinically important, indicating patients genuinely felt the difference day to day. A key laboratory marker of how well the underlying drug target is working, sweat chloride concentration, dropped substantially, bringing the average level in treated patients to just below the threshold typically used to diagnose cystic fibrosis. The treatment was generally well tolerated, with most side effects mild or moderate and very few patients stopping treatment because of them. This matters because patients with this particular mutation combination previously had no CFTR modulator therapy shown to work for them, leaving the underlying cause of their disease essentially untreated. The authors conclude that this triple-combination therapy is an effective new treatment option for this population and addresses the root cause of disease in the large majority of people with cystic fibrosis.